Summary of Investigation Results

Itraconazole

February 15, 2024

Non-proprietary name
Itraconazole

Brand name (marketing authorization holder)
a. Itrizole Capsules 50 (Janssen Pharmaceutical K.K.), and the others
b. Itrizole Oral Solution 1% (Janssen Pharmaceutical K.K.), and the others

Japanese market launch
a. August 1993
b. September 2006

Indications
See attachment.

Summary of revisions
“Pseudoaldosteronism” should be added to the Clinically Significant Adverse Reactions section in ADVERSE REACTIONS.

Investigation results and background of the revision
Cases involving pseudoaldosteronism were evaluated. Cases for which a causal relationship between itraconazole and pseudoaldosteronism was reasonably possible have been reported. As a result of consultation with expert advisors regarding the causality assessment of the cases and the necessity of revision of PRECAUTIONS, the MHLW/PMDA concluded that revision of PRECAUTIONS was necessary.
Reference: Number of cases* and patient mortalities involving pseudoaldosteronism reported in Japan and overseas

A total of 2 cases have been reported in Japan to date (including 1 case for which a causal relationship between the drug and event was reasonably possible).

No patient mortalities have been reported in Japan to date.

A total of 5 cases have been reported overseas to date (including 4 cases for which a causal relationship between the drug and event was reasonably possible).

No patient mortalities have been reported overseas to date.

*Cases collected in the PMDA's database for adverse drug reactions, etc. reports

The expert advisors present at the Expert Discussion regarding the current investigation were nominated based on their conflict of interest declarations concerning the relevant products, pursuant to the "Rules for Convening Expert Discussions, etc., by the Pharmaceuticals and Medical Devices Agency" (PMDA Administrative Rule No. 20-8, dated December 25, 2008).
<table>
<thead>
<tr>
<th>Brand name</th>
<th>Indications</th>
</tr>
</thead>
</table>
| a. Itrizole Capsules 50 | <Applicable microorganisms>  
Dermatophytes (genus *Trichophyton*, genus *Microsporum*, genus *Epidermophyton*), genus *Candida*,  
genus *Malassezia*, genus *Aspergillus*, genus *Cryptococcus*, genus *Sporothrix*, genus *Fonsecaea*  
<Applicable conditions>  
• Visceral mycosis (deep mycosis)  
  Fungaemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis  
• Deep cutaneous mycosis  
  Sporotrichosis, chromomycosis  
• Superficial cutaneous mycosis (excluding nail tinea)  
  Tinea: Body tinea, tinea cruris, tinea manuum, tinea pedis, tinea capitis, kerion celsi, tinea barbae  
  Candidiasis: Oral candidiasis, cutaneous candidiasis, nail candida, candidal paronychia and onychia,  
  candidal sycosis, chronic mucocutaneous candidiasis  
  Tinea versicolour, *Malassezia* folliculitis  
• Nail tinea |
| b. Itrizole Oral Solution 1% | • Fungal infection  
<Applicable microorganisms> |
<table>
<thead>
<tr>
<th>Brand name</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Genus <em>Aspergillus</em>, genus <em>Candida</em>, genus <em>Cryptococcus</em>, genus <em>Blastomyces</em>, genus <em>Histoplasma</em></td>
</tr>
<tr>
<td></td>
<td>&lt;Applicable conditions&gt;</td>
</tr>
<tr>
<td></td>
<td>Fungaemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, oropharyngeal candidiasis, oesophageal candidiasis, blastomycosis, histoplasmosis</td>
</tr>
<tr>
<td></td>
<td>• Prophylaxis of deep mycosis in patients with haematological malignancy or haematopoietic stem cell transplant patients who are expected to have neutropenia</td>
</tr>
</tbody>
</table>